GIP and type 2 diabetes mellitus: The study aims to characterize the secretion dynamics of glucagon-related peptides, including GLP-1, GIP, and GLP-2, across different stages of metabolic-associated steatotic liver disease (MASLD), while evaluating the impact of type 2 diabetes (T2D) on these hormonal responses.